search
Back to results

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes (AM7D)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Alogliptin
Metformin
Alogliptin Placebo
Metformin Placebo
Sponsored by
Takeda
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Type 2 Diabetes mellitus, Non-insulin dependent diabetes mellitus, Drug Therapy, Hypoglycemia,, Hyperglycemia

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has historical diagnosis of Type 2 Diabetes Mellitus.
  • Has been treated with diet and exercise for at least 2 months prior to Screening, and has a Glycosylated Hemoglobin concentration between 7.5% and 10.0%, inclusive at Screening.
  • Has received less than 7 days of any antidiabetic medication within 2 months prior to Screening.
  • Body mass index greater than or equal to 23 kg/m^2 and less than or equal to 45 kg/m^2 (except for Asian or Asian-descendant subjects for whom the range is between 20 and 35 kg/ m^2, inclusive).
  • Fasting C-peptide concentration greater than or equal to 0.8 ng/mL.
  • Regularly using other, non-excluded, medications must be on a stable dose for at least the 4 weeks prior to Screening.
  • Females of childbearing potential and males who are sexually active agree to routinely use adequate contraception from Screening throughout the duration of the study.
  • Able and willing to monitor their own blood glucose concentrations with a home glucose monitor and complete patient diaries.

Exclusion Criteria:

  • Hemoglobin less than 12 g/dL for males and less than 10 g/dL for females at Screening Visit.
  • Has a history of any hemoglobinopathy that may affect determination of Glycosylated Hemoglobin.
  • Has a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
  • Has a history of treatment for diabetic gastric paresis, gastric banding, or gastric bypass surgery.
  • Has a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.
  • Has systolic blood pressure greater than or equal to 150 mmHg and /or diastolic pressure greater than or equal to 90 mmHg at Screening visit.
  • Has New York Heart Association Class III to IV heart failure.
  • Has a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 90 days prior to Screening.
  • Has Alanine aminotransferase greater than 3 times the upper limit of normal at Screening.
  • Has a history of alcohol or substance abuse with the 2 years prior to Screening.
  • Serum creatinine greater than or equal to 1.5 mg/dL for males and greater than or equal to 1.4 mg/dL for females.
  • Has history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening.
  • Has a history of infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus.
  • Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
  • Has received any investigational drug within the 90 days prior to Screening.
  • Has a history of hypersensitivity or allergy to alogliptin, other DPP-4 inhibitors, metformin or related compounds.
  • Has used oral or systematically injected glucocorticoids or weight loss drugs prior to 2 months to screening.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Placebo Comparator

Experimental

Experimental

Active Comparator

Active Comparator

Experimental

Experimental

Arm Label

Placebo

Alogliptin 25 QD

Alogliptin 12.5 BID

Metformin 500 BID

Metformin 1000 BID

Alogliptin 12.5 BID + Metformin 500 BID

Alogliptin 12.5 BID + Metformin 1000 BID

Arm Description

Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.

Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.

Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.

Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.

Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.

Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.

Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.

Outcomes

Primary Outcome Measures

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).

Secondary Outcome Measures

Change From Baseline in HbA1c Over Time
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.
Change From Baseline in Fasting Plasma Glucose Over Time
The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.

Full Information

First Posted
December 1, 2009
Last Updated
February 17, 2013
Sponsor
Takeda
search

1. Study Identification

Unique Protocol Identification Number
NCT01023581
Brief Title
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
Acronym
AM7D
Official Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Takeda

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
Detailed Description
There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected. Metformin is the usual choice of first-line therapy for type 2 diabetes. Metformin targets insulin resistance in type 2 diabetes by inhibiting hepatic glucose production and stimulating glucose uptake in skeletal muscle and adipose tissue, which results in a long-term glucose-lowering effect. Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes. Based on the potential, complimentary mechanisms of action of alogliptin and metformin, this study will compare the safety and efficacy of alogliptin and metformin (SYR-322MET) on improving glycemic control in patients with type 2 diabetes mellitus who are inadequately controlled by diet adjustment and exercise alone. Participants taking part in this study will receive dietary and exercise coaching, and will monitor their own blood glucose concentrations with a home glucose monitor. Participants will also be required to maintain a hypoglycemic diary throughout the course of the study. Participation in this study is expected to last up to 34 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Type 2 Diabetes mellitus, Non-insulin dependent diabetes mellitus, Drug Therapy, Hypoglycemia,, Hyperglycemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
784 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
Arm Title
Alogliptin 25 QD
Arm Type
Experimental
Arm Description
Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
Arm Title
Alogliptin 12.5 BID
Arm Type
Experimental
Arm Description
Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
Arm Title
Metformin 500 BID
Arm Type
Active Comparator
Arm Description
Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
Arm Title
Metformin 1000 BID
Arm Type
Active Comparator
Arm Description
Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
Arm Title
Alogliptin 12.5 BID + Metformin 500 BID
Arm Type
Experimental
Arm Description
Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
Arm Title
Alogliptin 12.5 BID + Metformin 1000 BID
Arm Type
Experimental
Arm Description
Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.
Intervention Type
Drug
Intervention Name(s)
Alogliptin
Other Intervention Name(s)
SYR-322
Intervention Description
Alogliptin tablets.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucophage, Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Dianben, Diabex, Diaformin
Intervention Description
Metformin capsules
Intervention Type
Drug
Intervention Name(s)
Alogliptin Placebo
Intervention Description
Alogliptin placebo-matching tablets.
Intervention Type
Drug
Intervention Name(s)
Metformin Placebo
Intervention Description
Metformin placebo-matching capsules.
Primary Outcome Measure Information:
Title
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26
Description
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
Time Frame
Baseline and Week 26.
Secondary Outcome Measure Information:
Title
Change From Baseline in HbA1c Over Time
Description
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.
Time Frame
Baseline and Weeks 4, 8, 12, 16, and 20.
Title
Change From Baseline in Fasting Plasma Glucose Over Time
Description
The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.
Time Frame
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has historical diagnosis of Type 2 Diabetes Mellitus. Has been treated with diet and exercise for at least 2 months prior to Screening, and has a Glycosylated Hemoglobin concentration between 7.5% and 10.0%, inclusive at Screening. Has received less than 7 days of any antidiabetic medication within 2 months prior to Screening. Body mass index greater than or equal to 23 kg/m^2 and less than or equal to 45 kg/m^2 (except for Asian or Asian-descendant subjects for whom the range is between 20 and 35 kg/ m^2, inclusive). Fasting C-peptide concentration greater than or equal to 0.8 ng/mL. Regularly using other, non-excluded, medications must be on a stable dose for at least the 4 weeks prior to Screening. Females of childbearing potential and males who are sexually active agree to routinely use adequate contraception from Screening throughout the duration of the study. Able and willing to monitor their own blood glucose concentrations with a home glucose monitor and complete patient diaries. Exclusion Criteria: Hemoglobin less than 12 g/dL for males and less than 10 g/dL for females at Screening Visit. Has a history of any hemoglobinopathy that may affect determination of Glycosylated Hemoglobin. Has a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening. Has a history of treatment for diabetic gastric paresis, gastric banding, or gastric bypass surgery. Has a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma. Has systolic blood pressure greater than or equal to 150 mmHg and /or diastolic pressure greater than or equal to 90 mmHg at Screening visit. Has New York Heart Association Class III to IV heart failure. Has a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 90 days prior to Screening. Has Alanine aminotransferase greater than 3 times the upper limit of normal at Screening. Has a history of alcohol or substance abuse with the 2 years prior to Screening. Serum creatinine greater than or equal to 1.5 mg/dL for males and greater than or equal to 1.4 mg/dL for females. Has history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening. Has a history of infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus. Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study. Has received any investigational drug within the 90 days prior to Screening. Has a history of hypersensitivity or allergy to alogliptin, other DPP-4 inhibitors, metformin or related compounds. Has used oral or systematically injected glucocorticoids or weight loss drugs prior to 2 months to screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vice President, Clinical Science
Organizational Affiliation
Takeda
Official's Role
Study Director
Facility Information:
City
Dothan
State/Province
Alabama
Country
United States
City
Muscle Shoals
State/Province
Alabama
Country
United States
City
Pell City
State/Province
Alabama
Country
United States
City
Chandler
State/Province
Arizona
Country
United States
City
Mesa
State/Province
Arizona
Country
United States
City
Phoenix
State/Province
Arizona
Country
United States
City
Sierra Vista
State/Province
Arizona
Country
United States
City
Tempe
State/Province
Arizona
Country
United States
City
Little Rock
State/Province
Arkansas
Country
United States
City
Searcy
State/Province
Arkansas
Country
United States
City
Tempe
State/Province
Arkansas
Country
United States
City
Anaheim
State/Province
California
Country
United States
City
Buena Park
State/Province
California
Country
United States
City
Cathedral City
State/Province
California
Country
United States
City
National City
State/Province
California
Country
United States
City
Pismo Beach
State/Province
California
Country
United States
City
Roseville
State/Province
California
Country
United States
City
Santa Ana
State/Province
California
Country
United States
City
Colorado Springs
State/Province
Colorado
Country
United States
City
Boca Raton
State/Province
Florida
Country
United States
City
Bradenton
State/Province
Florida
Country
United States
City
Cutler Bay
State/Province
Florida
Country
United States
City
Hialeah
State/Province
Florida
Country
United States
City
Lauderdale Lakes
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
Ocala
State/Province
Florida
Country
United States
City
Opa Locka
State/Province
Florida
Country
United States
City
Orlando
State/Province
Florida
Country
United States
City
Panama City
State/Province
Florida
Country
United States
City
Pembroke Pines
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Blue Ridge
State/Province
Georgia
Country
United States
City
Decatur
State/Province
Georgia
Country
United States
City
Lawrenceville
State/Province
Georgia
Country
United States
City
Hayden Lake
State/Province
Idaho
Country
United States
City
Chicago
State/Province
Illinois
Country
United States
City
Melrose Park
State/Province
Illinois
Country
United States
City
La Porte
State/Province
Indiana
Country
United States
City
Mishawaka
State/Province
Indiana
Country
United States
City
Council Bluffs
State/Province
Iowa
Country
United States
City
Dubuque
State/Province
Iowa
Country
United States
City
Topeka
State/Province
Kansas
Country
United States
City
Lexington
State/Province
Kentucky
Country
United States
City
Louisville
State/Province
Kentucky
Country
United States
City
Marrero
State/Province
Louisiana
Country
United States
City
Oxon Hill
State/Province
Maryland
Country
United States
City
North Dartmouth
State/Province
Massachusetts
Country
United States
City
Dearborn
State/Province
Michigan
Country
United States
City
Flint
State/Province
Michigan
Country
United States
City
Kalamazoo
State/Province
Michigan
Country
United States
City
Picayune
State/Province
Mississippi
Country
United States
City
St. Louis
State/Province
Missouri
Country
United States
City
Omaha
State/Province
Nebraska
Country
United States
City
Henderson
State/Province
Nevada
Country
United States
City
Las Vegas
State/Province
Nevada
Country
United States
City
Brick
State/Province
New Jersey
Country
United States
City
Elizabeth
State/Province
New Jersey
Country
United States
City
North Massapequa
State/Province
New York
Country
United States
City
Asheville
State/Province
North Carolina
Country
United States
City
Charlotte
State/Province
North Carolina
Country
United States
City
Greensboro
State/Province
North Carolina
Country
United States
City
Mooresville
State/Province
North Carolina
Country
United States
City
Fargo
State/Province
North Dakota
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Cleveland
State/Province
Ohio
Country
United States
City
Gallipolis
State/Province
Ohio
Country
United States
City
Mason
State/Province
Ohio
Country
United States
City
Maumee
State/Province
Ohio
Country
United States
City
Norman
State/Province
Oklahoma
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Tulsa
State/Province
Oklahoma
Country
United States
City
Altoona
State/Province
Pennsylvania
Country
United States
City
Bensalem
State/Province
Pennsylvania
Country
United States
City
Downingtown
State/Province
Pennsylvania
Country
United States
City
Fleetwood
State/Province
Pennsylvania
Country
United States
City
Perkasie
State/Province
Pennsylvania
Country
United States
City
Shippensburg
State/Province
Pennsylvania
Country
United States
City
Tipton
State/Province
Pennsylvania
Country
United States
City
Uniontown
State/Province
Pennsylvania
Country
United States
City
Columbia
State/Province
South Carolina
Country
United States
City
Greenville
State/Province
South Carolina
Country
United States
City
Murrells Inlet
State/Province
South Carolina
Country
United States
City
North Myrtle Beach
State/Province
South Carolina
Country
United States
City
Taylors
State/Province
South Carolina
Country
United States
City
Brentwood
State/Province
Tennessee
Country
United States
City
Bristol
State/Province
Tennessee
Country
United States
City
Crossville
State/Province
Tennessee
Country
United States
City
Johnson City
State/Province
Tennessee
Country
United States
City
McKenzie
State/Province
Tennessee
Country
United States
City
Spring Hill
State/Province
Tennessee
Country
United States
City
Carrollton
State/Province
Texas
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
Deer Park
State/Province
Texas
Country
United States
City
El Paso
State/Province
Texas
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Hurst
State/Province
Texas
Country
United States
City
Katy
State/Province
Texas
Country
United States
City
Odessa
State/Province
Texas
Country
United States
City
San Antonio
State/Province
Texas
Country
United States
City
Schertz
State/Province
Texas
Country
United States
City
Spring
State/Province
Texas
Country
United States
City
Sugarland
State/Province
Texas
Country
United States
City
Temple
State/Province
Texas
Country
United States
City
Bountiful
State/Province
Utah
Country
United States
City
Ogden
State/Province
Utah
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States
City
South Burlington
State/Province
Vermont
Country
United States
City
Petersburg
State/Province
Virginia
Country
United States
City
Milwaukee
State/Province
Wisconsin
Country
United States
City
Hradec Kralove
Country
Czech Republic
City
Olomouc
Country
Czech Republic
City
Ostrava
Country
Czech Republic
City
Praha 10
Country
Czech Republic
City
Zlin
Country
Czech Republic
City
Znojmo
Country
Czech Republic
City
Budaors
Country
Hungary
City
Debrecen
Country
Hungary
City
Gyongyos
Country
Hungary
City
Gyor
Country
Hungary
City
Gyula
Country
Hungary
City
Komarom
Country
Hungary
City
Szolnok
Country
Hungary
City
Zalaegerszeg
Country
Hungary
City
Haifa
Country
Israel
City
Holon
Country
Israel
City
Kfar Saba
Country
Israel
City
Nahariya
Country
Israel
City
Safed
Country
Israel
City
Kaunas
Country
Lithuania
City
Kedainiai
Country
Lithuania
City
Klaipeda
Country
Lithuania
City
Vilnius
Country
Lithuania
City
Acapulco, Guerrero
Country
Mexico
City
Cuernavaca
Country
Mexico
City
Culiacan, Sinoloa
Country
Mexico
City
Distrito Federal
Country
Mexico
City
Durango, Durango
Country
Mexico
City
Durango
Country
Mexico
City
Guadalajara
Country
Mexico
City
Mexico City, Mexico
Country
Mexico
City
Mexico City
Country
Mexico
City
Mexico, DF
Country
Mexico
City
Monclova, Coahuila
Country
Mexico
City
Monterrey, NL
Country
Mexico
City
Monterrey
Country
Mexico
City
Pachuca, Hidalgo
Country
Mexico
City
Pachuca
Country
Mexico
City
Saltillo
Country
Mexico
City
Tijuana, Baja California
Country
Mexico
City
Zapopan, Jalisco
Country
Mexico
City
Bialystok
Country
Poland
City
Bytom
Country
Poland
City
Gniewkowo
Country
Poland
City
Grodzisk Mazowiecki
Country
Poland
City
Kamieniec Zabkowicki
Country
Poland
City
Leczyca
Country
Poland
City
Warszawa
Country
Poland
City
Wroclaw
Country
Poland
City
Caguas
Country
Puerto Rico
City
Cidra
Country
Puerto Rico
City
Ponce
Country
Puerto Rico
City
Salinas
Country
Puerto Rico
City
San Juan
Country
Puerto Rico
City
Santurce
Country
Puerto Rico
City
Trujilo Alto
Country
Puerto Rico
City
Bacau
Country
Romania
City
Baia Mare
Country
Romania
City
Bucharest
Country
Romania
City
Constanta
Country
Romania
City
Iasi
Country
Romania
City
Ploiesti
Country
Romania
City
Arkhangelsk
Country
Russian Federation
City
Irkutsk
Country
Russian Federation
City
Kemerovo
Country
Russian Federation
City
Moscow
Country
Russian Federation
City
Perm
Country
Russian Federation
City
St. Petersburg
Country
Russian Federation
City
Ufa
Country
Russian Federation
City
Banska Bystrica
Country
Slovakia
City
Kosice
Country
Slovakia
City
Lucenec
Country
Slovakia
City
Nitra
Country
Slovakia
City
Presov
Country
Slovakia
City
Prievidza
Country
Slovakia
City
Sahy
Country
Slovakia
City
Zilina
Country
Slovakia
City
Centurion
State/Province
Gauteng
Country
South Africa
City
Johannesburg
State/Province
Gauteng
Country
South Africa
City
Pretoria
State/Province
Gauteng
Country
South Africa
City
Durban
State/Province
Kwazulu-Natal
Country
South Africa
City
Cape Town
State/Province
Western Cape
Country
South Africa
City
Pretoria
Country
South Africa
City
Dnipropetrovsk
Country
Ukraine
City
Donetsk
Country
Ukraine
City
Ivano-Frankivsk
Country
Ukraine
City
Kharkiv
Country
Ukraine
City
Kyiv
Country
Ukraine
City
Lviv
Country
Ukraine
City
Odesa
Country
Ukraine
City
Vinnytsya
Country
Ukraine
City
Zaporizhzhya
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
24400655
Citation
Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014 Jul;16(7):613-21. doi: 10.1111/dom.12258. Epub 2014 Feb 12.
Results Reference
derived

Learn more about this trial

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs